PDCD1 and lung carcinoma: We constructed LL2 lung cancer subcutaneous model and H460 NSCLC xenograft model in mice to evaluate combinational therapy outcomes of JDB153 plus immunotherapy (PD‐1 Ab) and chemotherapy (cisplatin) respectively.